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KETAMINE IN THE TREATMENT OF DEPRESSION: CLINICAL UTILITY, 
SAFETY, AND MECHANISM OF ACTION 
NAKUL VYAS 
ABSTRACT 
Ketamine has shown promise as a novel treatment for depression and as a means to 
investigate the biology of depression. The drug effectively and rapidly treats depressed 
patients with the effects lasting approximately 1 week. However, concerns about 
ketamine’s efficacy do exist because of the inadequacy of blinding procedures used in 
existing trials. A dose of 0.5 mg/kg has been found to be most effective. Prolonged 
ketamine infusions have not extended the antidepressant effect beyond the timeframe of a 
regular infusion. Repeat infusions may be successful in extending ketamine’s effect, but 
definite conclusions cannot yet be made in this regard. Combination treatment with 
escitalopram and cognitive behavioral therapy (CBT) hold promise, as does the 
development of an intranasal formulation. Ketamine has shown additional efficacy as an 
acute anti-suicide treatment. Side effects from a single administration usually fade within 
a few hours and commonly include dissociation, elevations of blood pressure, nausea, 
and anxiety. Less data is available on the side effects caused by repeated ketamine 
infusions. Concerns exist regarding genitourinary, hepatic, and cognitive side effects after 
repeated infusions, as well as a risk of addiction. Research on ketamine’s mechanism of 
action has focused on the glutamate system in the brain. Ketamine may act by inhibiting 
release of γ–aminobutyric acid (GABA) from interneurons, activating intrasynaptic α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), increasing 
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mammalian target of rapamycin complex 1 (mTORC1) and extracellular signal-regulated 
kinase (ERK) signaling, enhancing brain-derived neurotrophic factor (BDNF) production, 
inhibiting glycogen synthase kinase 3 (GSK3), blocking extrasynaptic N-Methyl-D-
aspartate receptors (NMDARs), and promoting synaptogenesis and neuroplasticity. The 
two existing ketamine stereoisomers, (R)- versus (S)-ketamine, have different actions and 
potentially different efficacies and side effect profiles. Ketamine also produces regional 
changes in brain activity and connectivity. These include decreased burst firing in the 
lateral habenula (LHb), increased activity in the prefrontal cortex (PFC) and subgenual 
anterior cingulate cortex (ACC), and alterations in the amygdala’s response to angry and 
happy faces. Ketamine has the potential to be developed into a novel and useful clinical 
tool in the treatment of depression and to advance the understanding of the biology of 
depression. 
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BACKGROUND 
 
 In a given year in the United States, about 9.1% of the population experiences an 
episode of major depression. An additional 2.3% will experience bipolar depression in 
the same year. Over a lifetime, an estimated 16.8% of the U.S. population experiences 
major depression and 3.1% experiences bipolar depression (Kessler, Petukhova, 
Sampson, Zaslavsky, & Wittchen, 2012). Depression generates significant economic 
burden and disability. Unfortunately, several weeks are usually needed for current 
treatments to take effect. In addition, two-thirds of major depression patients do not 
respond to the medication initially prescribed (Li et al., 2010; Zarate et al., 2012). 
 Depression is also a prime risk factor for suicide. Among individuals that commit 
suicide, 90% have a psychiatric disorder. The psychiatric disorder is most often a mood 
disorder. Suicide is one of the top three causes of mortality worldwide for individuals 
aged 15 – 44 (Wilkinson, Ballard, et al., 2017). Of further concern, the suicide rate in the 
United States has been rising steadily since 2000 (Hedegaard, Curtin, & Warner, 2018). 
Current treatment options for acute suicide risk are limited. These treatment options most 
commonly consist of hospitalization, pharmacotherapy, psychotherapy, electroconvulsive 
therapy (ECT), or a combination thereof. Lithium, dialectical behavior therapy, and 
cognitive behavioral therapy (CBT) have been shown to reduce suicide deaths over the 
long-term, but have not been demonstrated to reduce deaths during acute treatment 
(Wilkinson, Ballard, et al., 2017). 
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 In this context, ketamine’s rapid onset of action and effectiveness in patients who 
have not responded to other treatments have generated considerable interest (Li et al., 
2010; Wilkinson, Ballard, et al., 2017). Ketamine has also generated excitement because 
the drug’s mechanism was thought to involve the glutamate system in the brain, rather 
than the monoamine systems that historically have been the major focus in treating 
depression (Sanacora, Zarate, Krystal, & Manji, 2008). Before turning to early studies on 
anti-depressant agents that act on the glutamate system, the operation of glutamate 
signaling in the brain will be outlined first. Then alterations of glutamate signaling in 
depressed patients will be catalogued.   
 
Overview of Glutamate Signaling 
 Glutamate is the brain’s main excitatory neurotransmitter. Glutamate binds 
ionotropic receptors, which occur in three types: kainate receptors, N-Methyl-D-aspartate 
receptors (NMDARs), and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptors (AMPARs; Figure 1). The binding of glutamate to these ionotropic receptors 
causes short-term changes in the post-synaptic cell’s membrane potential. Glutamate also 
binds metabotropic glutamate receptors (mGluRs), which alter processes within the cell 
through G proteins. Binding of glutamate to both ionotropic and metabotropic receptors 
can cause longer-term changes in synaptic strength through alterations in second 
messenger systems, transcription, and translation. 
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Figure 1: Glutamate Synapse. Three types of ionotropic glutamate receptors are present 
in the nervous system: kainate receptors, AMPARs, and NMDARs. When glutamate 
binds to these receptors, they respond by opening their ion channels. All three receptor 
ion channels are permeable to Na+ ions. The NMDAR ion channel is distinguished by its 
capacity to also allow a large number of Ca2+ ions to cross the plasma membrane. 
Calcium influx into the post-synaptic cell can, in turn, activate a number of second 
messenger systems that promote cell survival, protein synthesis, and AMPAR insertion 
into the plasma membrane. AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor; CaMK II, Ca2+/calmodulin-dependent protein kinase II; cAMP, cyclic 
adenosine monophosphate; CREB, cyclic adenosine monophosphate response element-
binding protein; MAPK, mitogen-activated protein kinase; NMDAR, N-Methyl-D-
aspartate receptor; PKA, protein kinase A; PKC, protein kinase C; TNFR1, tumor 
necrosis factor receptor 1. Figure from (Blaylock & Maroon, 2011). 
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 Though AMPARs, kainate receptors, and NMDARs have different channel 
structures, the opening of all three receptor channels permits Na+ to enter the cell. 
NMDARs are unique in that most of the inward current through the ion channel is carried 
by Ca2+. AMPARs are composed of four glutamate receptor subunits: GluR1 - GluR4. 
Glutamate binding to at least two of these subunits induces channel opening. Kainate 
receptors are tetramers composed of a combination of five possible subunits: GluR5, 
GluR6, GluR7, KA1, and KA2. NMDARs are composed of two NR1 and two NR2 
subunits. For the NMDAR channel to open, three actions must occur: the co-agonist 
glycine must bind to each of the NR1 subunits, glutamate must bind to each of the NR2 
subunits, and the Mg2+ atom that blocks the channel pore at rest must be displaced by 
initial depolarization through other receptors. Often AMPARs are responsible for this 
initial depolarization, which removes the Mg2+ from the NMDAR pore (Murrough, 
Abdallah, & Mathew, 2017). 
 The multiple requirements for opening the NMDAR channel endow the NMDAR 
with the capacity to serve as a “coincidence detector.” In its role as a coincidence 
detector, the NMDAR opens in response to multiple converging excitatory inputs on the 
neuron. Entry of calcium into the neuron through the NMDAR channel then activates 
second messenger pathways, including Ca2+/calmodulin dependent protein kinase II 
(CaMKII). Activation of CaMKII causes insertion of AMPARs into the plasma 
membrane (Murrough et al., 2017). Additional AMPARs in the membrane make the 
postsynaptic cell more likely to depolarize in response to subsequent stimulation 
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(Malenka & Nicoll, 1999). This strengthening of the synapse is called long-term 
potentiation (Malenka & Bear, 2004). 
 NMDAR signaling can promote cell survival or stimulate apoptosis depending on 
the duration of receptor activation and the location of the NMDAR relative to the 
synapse. Moderate NMDAR activation is neuroprotective, activating the RAS-mitogen-
activated protein kinase (RAS-MAPK) and cyclic adenosine monophosphate response 
element-binding protein (CREB) pathways. RAS-MAPK and CREB induce genes for cell 
survival. Induction by CREB increases brain-derived neurotrophic factor (BDNF)  
expression. On the other hand, over-release of glutamate and prolonged activation of 
NMDARs is associated with neuronal excitotoxicity. Activation of NMDARs within the 
synapse is neurotrophic. In contrast, activation of extrasynaptic NMDARs favors 
apoptosis (Murrough et al., 2017).  
 Glial cells are also important modulators of glutamate signaling. Glial cells 
remove glutamate from the synapse through excitatory amino acid transporters (EAATs) 
and convert the glutamate to glutamine (Figure 2). Via glycine transporter 1, glial cells 
also remove glycine from synapses (Murrough et al., 2017). Astrocytes synthesize and 
release the trophic factors BDNF and glial-derived neurotrophic factor, which enhance 
maintenance of glutamatergic synapses and neuronal survival (Murrough et al., 2017; 
Sanacora & Banasr, 2013).  
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Figure 2: Glutamate/Glutamine Metabolism in Glial Cells Around Synapse. Glial 
cells, shown in peach, clear glutamate from the synapse through excitatory amino acid 
transporters (EAATs). The glial cells metabolize glutamate to glutamine using glutamine 
synthetase. The glutamine can then be transported to the pre-synaptic neuronal terminal, 
where the glutamine can be converted back to glutamate using glutaminase. The 
glutamate can then be released into the synapse to bind to receptors on the post-synaptic 
neuronal terminal. The pre-synaptic and post-synaptic neuronal terminals are shaded 
blue. AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ADP, adenosine 
diphosphate; ATP, adenosine triphosphate; EAAT, excitatory amino acid transporter; 
NMDA, N-Methyl-D-aspartate; mGluR, metabotropic glutamate receptor; Pi, inorganic 
phosphate; xCT, cysteine-glutamate antiporter. Figure from (Kritis, Stamoula, Paniskaki, 
& Vavilis, 2015).  
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Alterations in Glutamate Transmission in Depression 
 Depressed patients show a number of abnormalities of glutamate signaling in the 
brain. Elevated glutamate has been found in fluid samples, genetic analyses, and post-
mortem studies of depressed patients. Chronic stress alters glutamatergic transmission in 
both human and animal studies. Brain imaging research has also found alterations in 
glutamate signaling in various brain regions. 
 Serous fluid assays, post-mortem, and genetic studies all show evidence of 
glutamate system abnormalities that accompany depression. Plasma, cerebrospinal, and 
brain glutamate levels are increased in depressed patients. Additionally, a small number 
of genetic studies have shown an association between depression and particular genes 
related to glutamate signaling. Though there are some inconsistencies regarding the 
direction of effect in various brain regions, elevated glutamate has been found in post- 
mortem studies of depressed patients. Post mortem studies have also showed altered 
NMDAR function or expression in patients with major depressive disorder (MDD), 
bipolar disorder, and those who died from suicide (Murrough et al., 2017). 
  In animal and human studies, chronic stress is associated with depression. 
Animals subjected to chronic stress show altered glutamine release and reuptake. In these 
animals, glia take in less extracellular glutamate than normal, raising the extracellular 
glutamate concentration around neurons. The heightened extracellular glutamate 
increases activation of extrasynaptic NMDARs, whose activation in turn degrades 
synapse function and causes apoptosis of neurons (Murrough et al., 2013). In prefrontal 
cortex (PFC) neurons of rats under chronic stress, AMPAR and NMDAR subunits 
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decrease as a consequence of ubiquitin–proteasome-dependent degradation. Across the 
PFCs of these rats, synaptic spine density and dendritic complexity decreases (Popoli, 
Yan, McEwen, & Sanacora, 2012). The decreased intrasynaptic glutamatergic and 
increased extrasynaptic glutamatergic signaling associated with chronic stress also    
reduces BDNF signaling within hippocampal and cortical glutamatergic synapses. 
Patients with mood disorders have been shown to have fewer glia in their PFCs 
(Murrough et al., 2017). Animal studies also indicate that chronic stress may disrupt 
astrocyte function by reducing glial fibrillary associated protein, a component of 
astrocyte cytoskeletons (Banasr et al., 2010). 
 Elevated glutamate has been found in brain imaging of depressed patients. 
However, the direction of effect may differ across brain regions. Proton magnetic 
resonance spectroscopy (1H-MRS) shows a reduced glutamate plus glutamine signal in 
the PFCs of patients with MDD. The same method found that γ–aminobutyric acid 
(GABA) levels are reduced in the PFC and occipital cortex, while glutamate levels in the 
occipital cortex are increased (Murrough et al., 2017). A study using 13C magnetic 
resonance spectroscopy found that the oxidative energy production of glutamatergic 
neurons is reduced by 26% in patients with MDD without any decrease in glutamate-
glutamine cycling (Abdallah et al., 2014). 
 
Early Studies of NMDAR Antagonists 
 In the 1990s, a research group performed a preliminary set of experiments to 
assess whether NMDAR antagonists had antidepressant effects in animal models. Three 
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such agents were discovered to reduce mouse immobility in the forced swim test in a 
dose dependent fashion. These were dizocilpine (MK-801), an NMDAR channel blocker; 
2-amino-7-phosphonoheptanoic acid (AP-7), a competitive antagonist at the NMDAR; 
and 1-aminocyclopropanecarboxylic acid (ACPC), an NMDAR glycine site partial 
antagonist. In follow-up experiments, imipramine, citalopram, and ECT were all found to 
affect transmission at NMDARs in a long lasting fashion. The group proposed that 
modulation of NMDARs might be the final common pathway of all antidepressants 
(Murrough et al., 2017).   
 The first clinical study to test whether ketamine had antidepressant effects in 
humans was a study in 2000 by Berman et al. (Murrough et al., 2017). As a preliminary 
study, the sample size was nine patients. Ketamine was found to significantly reduce 
Hamilton Depression Rating Scale (HDRS) scores in comparison to saline. Mood 
returned to pre-treatment baseline within one or two weeks. The individual HDRS items 
that underwent statistically significant improvement were depressed mood, helplessness, 
and worthlessness.  
 In this initial study (Berman et al., 2000), ketamine administration produced 
substantial, but transient cognitive deficits and euphoria. The euphoria or “high” returned 
to baseline within hours. However, the decrease in depressive symptoms occurred 
progressively across three days. The differing timelines suggested to the authors a 
disconnect between the euphoric and antidepressant effects of ketamine. 
 In 2006, Zarate et al. tested ketamine’s ability to treat MDD in a trial of 18 
treatment resistant patients — defined here as patients who did not respond to at least one 
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adequate trial of an antidepressant. They found ketamine, within hours of administration, 
had robust antidepressant activity in this population. For 71% of patients, symptoms 
decreased in severity by at least one half. 
 Regarding the mechanism of action, Zarate et al. (2006) argued that the delayed 
therapeutic effect of traditional monoaminergic drugs could be accounted for by the 
delayed effects of these monoaminergic drugs on downstream neurotrophic signaling 
cascades and glutamate transmission. The changes in these signaling cascades and the 
glutamate system then cause improvements in mood (Zarate et al., 2006).  
 Following these initial studies, research on ketamine and depression has 
multiplied. In the effort to understand the neurobiology of depression, Duman & 
Aghajanian (Duman & Aghajanian, 2012) recently characterized ketamine’s rapid 
antidepressant effect as “arguably the most important discovery in half a century.” In 
March 2019, the Food and Drug Administration approved an intranasal formulation of 
ketamine for treating depressed patients unresponsive to previous treatments (Farchione, 
2019). 
 This thesis will outline three aspects of ketamine’s use in the treatment of 
depression. First, ketamine’s efficacy and clinical utility in the treatment of depression 
will be assessed. Second, the safety and tolerability of ketamine in this group of patients 
will be described. Third, hypothesized mechanisms of action for ketamine’s 
antidepressant effect will be explored. 
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Specific Aims 
The specific aims of this thesis are: 
1. Evaluation of the effectiveness and clinical utility of ketamine in the treatment of 
depression. 
2. Examination of ketamine’s safety and tolerability in depressed patients. 
3. Description of proposed mechanisms of action underlying ketamine’s 
antidepressant effect. 
 
		
12 
EFFICACY AND CLINICAL UTILITY 
  
 Ketamine alleviates depression within hours and patients often benefit from the 
effects for up to one week after the infusion. The drug is more effective than placebo in 
both unipolar and bipolar depression, but has the greater effect in unipolar depression. An 
intravenous ketamine dose of 0.5 mg/kg infused within 40 minutes has been found to 
maximize improvements in mood while avoiding the greater side effects caused by higher 
doses. 
 Combination treatments and non-intravenous routes of administration have been 
tested in an effort to broaden ketamine’s clinical utility. Repeated ketamine infusions 
may potentially extend antidepressant effects beyond what is typically seen with a single 
infusion; in contrast, prolonged ketamine infusions do not appear to extend the duration 
of action. Combining ketamine with escitalopram or CBT may enhance and prolong 
antidepressant effects. Treating patients with D-cycloserine following ketamine infusion 
does not prolong antidepressant effects beyond the single week in which ketamine 
typically acts. Besides intravenous infusion, ketamine has also shown antidepressant 
effects when administered by oral, sublingual, and nasal routes.  
 Ketamine may also be useful in preventing suicide. Within one day, ketamine 
decreases suicidal ideation. Upwards of 25% of patients are free of suicidal ideation for a 
week. The drug has the potential to be developed as an alternative to ECT in the 
treatment of suicidality.  
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 Alongside evidence in favor of ketamine’s utility as an antidepressant and anti-
suicide agent, concerns exist about ketamine’s effectiveness. Doubt about the integrity of 
blinding procedures burdens many studies. Some researchers and clinicians also worry 
that ketamine is a euphoriant rather than an antidepressant. 
 
Remission and Response Rates 
 Ketamine infusion produces an anti-depressant effect within two hours. The 
effects are significant when measured with the Beck Depression Inventory, the 
Montgomery-Åsberg Depression Rating Scale (MADRS), the HDRS, and other measures 
of depression. The impact is greatest on the day of the infusion and antidepressant effects 
are sustained for about a week. No other treatment is known to combine such rapidity of 
action with a relatively sustained effect (Wilkinson, Ballard, et al., 2017; Zarate et al., 
2006).  
 A meta-analysis composed of seven randomized control trials (RCTs) found 
ketamine to have a nearly 10 fold higher likelihood of inducing a response one day after 
treatment in comparison to control (Newport et al., 2015). Response is defined here and 
throughout this thesis as a 50% reduction of depressive symptoms from baseline, unless 
otherwise noted. One day following treatment, 53% of patients achieved response.  
 The same meta-analysis found ketamine, one day following treatment, to have a 
14 fold higher likelihood of inducing remission of depressive symptoms versus control 
(Newport et al., 2015). Remission of depression is defined as having minimal to no 
symptoms and a return to normal function. However, no standardized exact criteria for 
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remission exists and the criteria can vary across studies (Israel, 2006), as was the case in 
this meta-analysis (Newport et al., 2015). The meta-analysis showed that 30% of patients 
achieved remission one day after treatment. 
 In the Newport et al. (2015) meta-analysis, response and remission rates declined 
one week after ketamine treatment, but a clinically meaningful antidepressant effect 
persisted for a subset of patients. Response was retained by 31% of patients and 
remission by 15%.  
 
Unipolar Versus Bipolar Depression 
 A meta-analysis of eight RCTs (McGirr et al., 2015) found ketamine to be more 
effective than placebo in treating both unipolar depression and bipolar depression. 
However, ketamine appeared to have a greater antidepressant effect in unipolar 
depression. The effect size for unipolar patients was a standardized mean difference of 
1.07 between ketamine and control; for bipolar patients, the standardized mean difference 
was 0.68. Additionally, ketamine did not seem to produce mania or psychotic symptoms 
in the bipolar patients, although the number of patients with bipolar depression in the 
sample was small. Of the 34 patients with bipolar depression, the only patient to 
experience mania was receiving saline control.  
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Dosing 
 Almost all ketamine trials for depression have used a parenteral dose of 0.5 mg/kg 
infused over 40 minutes (Murrough et al., 2017). A one-month National Institute of 
Mental Health RCT of 99 patients examined four intravenous doses of ketamine. Doses 
of 0.5 mg/kg and 1 mg/kg alleviated depression significantly more than the midazolam 
control. Doses of 0.1 mg/kg and 0.2 mg/kg were not superior to control. Doses of 0.5 
mg/kg and 1 mg/kg did not show a statistically significant difference in antidepressant 
effects, but the 0.5 mg/kg dose actually produced the greater numerical decrease in 
depression scores. Compared to the 0.5 mg/kg dose, the 1 mg/kg dose caused greater 
percentages of patients to experience adverse events — including dissociative and 
elevated blood pressure side effects (Fava et al., 2018).  
 
Repeated and Prolonged Ketamine Infusions 
 While an attenuation of symptoms for one week is meaningful, a key concern is 
finding a way to maintain ketamine’s anti-depressant effect. Researchers have attempted 
to extend ketamine’s duration of action by administering repeated ketamine infusions and 
prolonged ketamine infusions.  
 An open-label study of 24 patients with treatment resistant depression examined 
the effect of repeated ketamine infusions. Treatment resistant depression was defined in 
this study as a depressive episode that has resisted at least two Food and Drug 
Administration approved antidepressant treatments. Six ketamine infusions across a 12-
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day period produced a mean time to relapse among ketamine responders of 18 days after 
the last infusion. Subjects displayed significant variability with some maintaining 
response for more than 83 days (Murrough et al., 2013). The best dosing frequency for 
repeated infusions (daily vs. more intermittently) is still currently unknown (Murrough et 
al., 2017). 
 A second study (Lenze et al., 2016) compared the effects of a 96-hour ketamine 
infusion to a 40-minute ketamine infusion. Clonidine was administered to attenuate the 
psychotomimetic and sympathomimetic side effects produced by the infusion. Though 
not formally tested, the clonidine did seem to prevent most psychotomimetic side effects 
and limit blood pressure elevations to clinically insignificant levels. However, no 
significant difference was found between the 96-hour and 40-minute groups in the time 
that ketamine’s antidepressant effect was maintained after the infusion. The sample size 
in this study (10 subjects) limited statistical power. These two studies (Lenze et al., 2016; 
Murrough et al., 2013) illustrate the significant challenges that remain in extending 
ketamine’s duration of action. 
 
Combination Treatments 
 Ketamine has been combined with other treatments to accelerate, enhance, or 
extend ketamine’s therapeutic effect. The selective serotonin reuptake inhibitor 
escitalopram has been given along with ketamine to achieve antidepressant response and 
remission more quickly and extend antidepressant effects beyond what is usually 
achieved with a single ketamine infusion. Following ketamine infusions, D-cycloserine 
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has also been given to patients to try to enhance and extend ketamine’s antidepressant 
effect. Lastly, CBT has been used to try to extend the antidepressant effect attained 
through ketamine infusion. 
 An RCT (Y.-D. Hu et al., 2016) examining 30 outpatients with MDD found that 
augmenting escitalopram treatment with a single ketamine administration quickened the 
onset of antidepressant effects in comparison to escitalopram treatment alone. In this 
study remission was defined as a MADRS score of less than 10. Such a MADRS score 
corresponds with recovery or only mild symptoms (Müller, Szegedi, Wetzel, & Benkert, 
2000). Four weeks after receiving ketamine or saline and beginning escitalopram 
treatment, patients in the ketamine group had higher response and remission rates in 
comparison to the saline group. The mean time to reach response was shorter with 
ketamine: six days for the ketamine group versus 27 days for the saline group. More 
patients did experience at least one adverse event in the ketamine group, but no patients 
discontinued treatment as a consequence (Y.-D. Hu et al., 2016). 
 D-cycloserine is an antituberculosis drug that shows antidepressant effects after 
eight weeks of treatment. Like ketamine, D-cycloserine inhibits NMDARs. Seven 
subjects received open-label ketamine, followed by eight weeks of D-cycloserine. An 
improvement after ketamine predicted improvement with D-cycloserine. However, a 
partial relapse at two weeks indicated that ketamine and D-cycloserine exerted 
antidepressant effects independently during the first two weeks and after eight weeks, 
respectively. In other words, although D-cycloserine may possess its own antidepressant 
effects, there was no indication that D-cycloserine extended ketamine’s antidepressant 
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effect or acted synergistically with ketamine to enhance ketamine’s antidepressant effects 
(Kantrowitz, Halberstam, & Gangwisch, 2015). 
 One study has shown CBT augmenting ketamine’s effect over a longer time 
period compared to ketamine monotherapy. In the open-label study, four ketamine 
treatments were given over two weeks. Concurrently, the patients received 10 weeks of 
CBT. Among the patients that responded to ketamine, 75% had not relapsed eight weeks 
after the final ketamine exposure. The median time to relapse for ketamine responders 
was 12 weeks with CBT. The result compares favorably with similar open-label ketamine 
monotherapy studies, in which the number of responders who had not relapsed at only 
four weeks ranged from 89 – 55%. In these ketamine monotherapy studies without CBT, 
median time to relapse was about three weeks (ranging from 17 – 25 days). However, the 
small sample size and lack of a control group in this study make these results preliminary 
(Wilkinson, Wright, et al., 2017).  
 
Other Routes of Administration 
 A current limitation for ketamine in the treatment of depression is that the drug 
must be administered intravenously, limiting its use in outpatient settings (Daly et al., 
2018). In the first paper (Berman et al., 2000) to examine ketamine’s antidepressant 
effect in humans, the authors speculated that the intravenous route of administration 
might at least partially account for ketamine’s rapid effect. They note that some studies of 
intravenously administered tricyclic antidepressants show similarly rapid antidepressant 
effects. Subsequent studies of ketamine administered orally, sublingually, and nasally 
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have shown roughly comparably antidepressant effects to ketamine administered 
intravenously, though oral administration does not achieve an antidepressant effect as 
rapidly.    
 An open-label study of oral ketamine (Irwin et al., 2013) gave patients with 
depression a daily oral dose of 0.5 mg/kg ketamine for 28 days. Response rates in this 
study — assessed here by the Hospital Anxiety and Depression Scale — were similar to 
those for intravenous ketamine. However, this study defined response atypically as a 30% 
or more decrease in depression scores. Additionally, antidepressant effects took longer to 
take hold: in comparison to before treatment, the decrease in depression did not become 
significant until 14 days after treatment. The antidepressant effect remained significant 
compared to baseline until the end of the study at day 28. Anxiolytic effects became 
significant on the third day. Few adverse events were recorded. One subject each reported 
mild complaints of diarrhea, insomnia, and akathisia.  
 An open-label study of sublingual administration (Lara, Bisol, & Munari, 2013) 
found a comparable response rate (77%) to intravenous studies. However, the 
improvement necessary for a response was not defined in this study. No standardized 
diagnostic scales were used; instead, clinicians assigned response and remission 
designations to patients according to the reports of patients and relatives. Unipolar or 
bipolar depression patients sublingually absorbed ketamine doses of 10 mg drawn from a 
100 mg/ml solution for five minutes and then swallowed the dose. The 26 subjects in the 
study received doses every two to three days or on a weekly basis. Side effects were mild. 
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A lightheadedness that subsided within 30 minutes of the dose was commonly 
experienced. 
 Esketamine, the S-enantiomer of ketamine, has been developed as an intranasal 
formulation. In a 2017 RCT sponsored by Janssen Research & Development that 
evaluated the intranasal formulation (Daly et al., 2018), the participants had failed one to 
three previous antidepressants. Patients received placebo, 28 mg, 56 mg, or 84 mg 
esketamine twice weekly for two weeks. After that, in a nine-week open label phase, all 
patients received esketamine twice weekly for the first two weeks, weekly for the next 
three weeks, and then once every two weeks for the remaining four weeks. Lastly, 
patients were followed another eight weeks in a follow-up phase without any further 
administration of ketamine. 
 At the 24-hour and one-week time points following treatment, there was a 
statistically significant decrease in MADRS scores in all esketamine groups compared to 
placebo. There was some further decrease in MADRS scores with repeated dosing, as 
seen in the open label phase. Notably, in the eight-week follow-up phase, the decrease in 
MADRS scores was maintained for the majority of participants without any further 
ketamine doses during those eight weeks. With the lowest dose (28 mg), the duration of 
efficacy beyond the treatment period seemed to be shorter and fewer patients achieved a 
50% reduction in symptoms.   
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Use for Suicide Prevention 
 Does ketamine diminish suicidal ideation more quickly than control? Is the anti-
suicide effect independent of ketamine’s diminution of other symptoms of depression? 
Wilkinson et al., 2017 used systemic review and meta-analysis to examine ketamine’s 
effectiveness as an anti-suicide agent. Only single dose, comparison intervention trials 
using saline and midazolam as controls were included. Wilkinson et al., 2017 identified 
11 relevant trials, encompassing 167 patients who presented with suicidal ideation.  
 The meta-analysis found that ketamine diminished suicidal ideation more quickly 
than control treatments as demonstrated by two clinician rating scales: the MADRS and 
HDRS. Ketamine also significantly increased the number of patients free from suicidal 
ideation as assessed by these clinician-administered rating scales. A substantial effect was 
observed as early as day one and the effect extended for up to a week. Effect sizes were 
large to moderate (d = 0.85 on day one and d = 0.61 on day seven). Self-report measures 
of suicidal ideation — namely, items of the Quick Inventory of Depressive 
Symptomatology–Self Report (QIDS-SR) and the Beck Depression Inventory — showed 
a similarly significant reduction after ketamine infusion. 
 Ketamine’s reduction of suicidal ideation occurred equally across age, gender, 
race, concomitant use of psychotropics, and outpatient versus inpatient status covariates. 
Over half of participants reported no suicidal ideation for one week after infusion. For 
one patient to be free of all suicidal ideation across the entire first week post-infusion, the 
number needed to treat was 3.1 – 4 patients. 
		
22 
 Reduction of depressive symptoms and suicidal ideation were highly correlated 
across the first week after infusion. After controlling for the decrease in depression 
symptoms, ketamine’s reduction of suicidal ideation continued to be significant. This 
indicates ketamine had a specific effect on suicidal ideation beyond its more general 
antidepressant effects.  
 ECT is the standard of care for patients with acute suicidal ideation and a mood 
disorder. Wilkinson, Ballard, et al. (2017) performed a comparison between ketamine 
infusion results from their meta-analysis and an open-label ECT trial. Within 24 hours of 
a single ketamine infusion, 55% of patients were free of suicidal ideation. One week post-
infusion, 60% were free of suicidal ideation. In contrast, 38% of patients were free of 
suicidal ideation after three ECT treatments in a single week. Within a one-week 
timespan then, ketamine is potentially a superior treatment. 
 However, over a longer period of time, the available evidence favors the use of 
ECT. After six ECT treatments (occurring over two weeks following the start of 
treatment), 61% of patients were free of suicidal ideation. At the end of the acute course 
of ECT treatment (on average 7.5 treatments with ECT administered on a thrice weekly 
schedule), 81% of patients were free of suicidal ideation. The ketamine meta-analysis did 
not include data beyond one week so a direct comparison with ECT cannot yet be made 
beyond one week (C. H. Kellner et al., 2005; Wilkinson, Ballard, et al., 2017).  
 Repeated ketamine infusions, however, could have longer lasting anti-suicide 
effects beyond acute treatment, unlike repeated ECT. After acute ECT treatment, relapse 
rates for depression and suicidal ideation are substantial if further treatment is not 
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sustained (C. H. Kellner et al., 2005; J. Prudic & Sackeim, 1999). For example, in an 
observational study of 154 patients who were followed after remission with ECT 
treatment, 64% of patients relapsed within six months (Joan Prudic, Olfson, Marcus, 
Fuller, & Sackeim, 2004). Remission after ECT treatment was defined in that study as at 
least a 60% reduction in HDRS score and an HDRS score of less than 10. In comparison, 
the eight week follow-up phase of the intranasal study of ketamine (Daly et al., 2018) 
indicates the potential for sustained resolution of depressive symptoms with repeated 
ketamine treatments. If suicidal ideation is assumed to have decreased along with 
depression, repeated intranasal ketamine has the potential to treat suicidal ideation for 
weeks after the treatment ends. However, the intranasal study of ketamine excluded 
patients with any current or recent suicidal ideation. As such, the effectiveness of 
repeated ketamine treatments as an anti-suicide agent beyond acute treatment is currently 
unproven (Daly et al., 2018).  
 Ketamine also potentially has a more favorable side effect profile than ECT, 
although ketamine’s long-term side effects have not yet been rigorously studied (see 
Safety and Tolerability section below). Medical adverse effects caused by ECT include 
cardiopulmonary events, fractures, dental injuries, and tongue wounds. Cognitive adverse 
effects caused by ECT include confusion, retrograde amnesia, and anterograde amnesia 
(C. Kellner, 2018). Rates of persistent memory loss after ECT ranged from 29% to 55% 
(Rose, Fleischmann, Wykes, Leese, & Bindman, 2003). 
 Most of the patients in the meta-analysis evaluating ketamine’s effectiveness 
against suicide (Wilkinson, Ballard, et al., 2017) were patients who had MDD or bipolar 
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depression. Future studies might examine ketamine’s effectiveness as an anti-suicide 
agent across a wider range of diagnoses. In particular, patients with a substance use 
disorder or schizophrenia/schizoaffective disorder were excluded from the populations 
studied in the meta-analysis.  
 A second limitation of the included studies is that they only assess suicidal 
ideation rather than suicidal behavior. Only one of the 11 studies included patients 
believed to be at immediate risk of suicide. Additionally, patient outcomes were not 
monitored beyond one week after the ketamine infusion (Wilkinson, Ballard, et al., 
2017).  
 
Concerns About Efficacy 
 Among the studies evaluating ketamine’s effectiveness as an antidepressant and 
anti-suicide agent, a concern recurs about the integrity of the blinding method (Murrough 
et al., 2017). For example, in Berman et al. (2000) and Fava et al. (2018) patients could 
readily discern whether they received ketamine or saline. Studies that used saline as a 
comparator had larger effect sizes than those that used midazolam (Wilkinson, Ballard, et 
al., 2017). Unblinding may occur in studies that use midazolam as well, as occurred in 
Fava et al. (2018).  
 A second concern centers on whether ketamine is a bona fide antidepressant or is 
simply a euphoriant (Schatzberg, 2014). However, as noted in Berman et al. (2000), the 
timeline of events following ketamine administration does seem to distinguish between 
euphoric and antidepressant effects. Zarate et al. (2006) demonstrated that ketamine’s 
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euphoric effects returned to baseline within 110 minutes of infusion for all patients, as 
assessed by the Young Mania Rating Scale. In contrast, ketamine’s antidepressant effect 
lasts for approximately one week (Zarate et al., 2006). 
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SAFETY AND TOLERABILITY 
 
 Ketamine is considered safe as an anesthetic. However, as an anesthetic, ketamine 
is usually only given to a patient as a one-time dose (Short, Fong, Galvez, Shelker, & 
Loo, 2018). Such single doses of ketamine generally only produce acute side effects that 
resolve within hours of the administration. In contrast, less is known about the side 
effects that may result following multiple ketamine administrations. With repeated 
ketamine doses, concerns exist about genitourinary, hepatic, and cognitive adverse effects 
as well as the risk of dependency. A small number of studies on other routes of ketamine 
administration aside from the most commonly used intravenous route (e.g., intranasal) 
have been performed. In comparison to the side effect profile of intravenous 
administration, these other routes show a largely similar mix of side effects. 
 
Single Doses 
 In treating depression, ketamine is generally safe and well-tolerated when used 
under supervision in single doses. Ketamine infusions can induce perceptual 
disturbances, confusion, elevated blood pressure, euphoria, and dizziness among other 
side effects. However, these adverse events mostly dissipate within 80 minutes of the 
infusion (Zarate et al., 2006). Other side effects commonly reported are blurred vision 
and nausea (Short et al., 2018).   
 A meta-analysis of 60 studies (Short et al., 2018) found that the most common 
psychiatric short-term side effect was anxiety. The anxiety was generally acute and self-
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limited. Other psychiatric side effects included agitation, irritability, euphoria, delusions, 
unusual thoughts, apathy, and panic. These side effects, too, tended to be acute and self-
limiting. 
 The same meta-analysis (Short et al., 2018) found that the most common 
psychotomimetic side effect was dissociation. Other psychotomimetic side effects include 
perceptual disturbances, odd or abnormal sensations, derealization, hallucinations, feeling 
strange or unreal, and depersonalization. These side effects also dissipate within a few 
hours of the infusion. No long-term psychotomimetic side effects have been observed. 
 In Short et al. (2018), the most common cardiovascular changes were increased 
blood pressure and heart rate. In general, these cardiovascular changes returned to 
baseline within 90 minutes (Short et al., 2018). The mechanism causing the transient 
increase in blood pressure is thought to be an increase in cardiac output (Daly et al., 
2018). 
 Cognitive side effects encompass poor memory, decreased concentration, 
confusion, and diminished mental capacity. The available studies have largely 
documented these acute effects only occurring within four hours of the ketamine 
infusion. However, most studies did not assess cognitive side effects (Short et al., 2018). 
An RCT (Murrough et al., 2015) found ketamine administration to have no difference 
from midazolam in terms of cognitive effects one week following administration. In that 
study, neurocognitive performance was measured before drug administration and seven 
days after. Performance actually improved in both the ketamine and midazolam groups at 
seven days, likely as the result of a general learning effect.  
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Repeated Doses 
 There is less data available on the safety of multiple doses of ketamine (Short et 
al., 2018). The acute side effects mentioned above — most prominently dissociative 
effects and elevations in blood pressure — do occur with repeated infusions, but remain 
mild and do not increase in severity (Murrough et al., 2013). In evaluating ketamine’s 
acute side effects (and also effectiveness), RCTs are useful. However, these trials tend to 
last a short period of time and use a limited number of doses and participants (Short et al., 
2018). The meta-analysis of 60 studies examining side effects of ketamine administration 
(Short et al., 2018) found that long-term side effects were only examined in 20% of 
studies. In consequence, most of the available literature is not well suited to ascertaining 
long-term side effects or rare adverse events. 
 Individuals who have used ketamine over a longer period of time — namely, 
individuals with chronic pain and recreational users — show a number of adverse 
outcomes. Urinary tract symptoms and liver toxicity has been documented in these 
populations. Chronic recreational users of ketamine also show cognitive impairments 
(Short et al., 2018). Additionally, ketamine does have addictive properties. The risk of 
dependency constrains the drug’s widespread use (Morgan & Curran, 2012; Zanos et al., 
2016). 
 Short et al. (2018) report several genitourinary symptoms in chronic ketamine 
users, including cystitis, bladder dysfunction, an increase in urinary frequency and 
urgency, urge incontinence, and rarely hematuria with pain. In severe cases, renal damage 
has also been documented. The mechanism underlying ketamine’s urological symptoms 
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are unknown. An in vitro study has shown that ketamine causes urothelial cells to 
apoptose. It is unclear if such damage to the bladder urothelium is reversed after ceasing 
ketamine use. Out of 60 studies in this review, urinary side effects were only assessed in 
five studies. The Independent Scientific Committee on Drugs (Morgan & Curran, 2012) 
determined that daily ketamine use is associated with ulcerative cystitis. 
 Hepatotoxicity has been reported following repeated or prolonged ketamine 
infusions. The mechanism underlying liver toxicity in ketamine users is also unknown. 
Enhanced free radical formation and lipid peroxidation, increased flow resistance across 
the Sphincter of Oddi, or dilatation of the biliary tree and gallbladder dyskinesia may 
play a role in this toxicity. Liver function tests were reported in seven of 60 studies. Two 
of these studies showed liver abnormalities following ketamine administration (Short et 
al., 2018).  
 Compared to healthy controls without a history of drug addiction, frequent 
recreational ketamine users can show substantial impairments of short and long-term 
memory. Chronic ketamine users exhibit an upregulation of dopamine receptor D1 
availability in the dorsolateral PFC. The same effect is seen in animals subject to chronic 
dopamine depletion. Disruption of dopaminergic transmission by ketamine may mediate 
disruption of working memory and executive control (Short et al., 2018). Daily ketamine 
use is also associated with working and episodic memory impairments according to 
Morgan and Curran (2012). 
 However, the presence of cognitive deficits in non-recreational repeat users of 
ketamine — namely, depression and chronic pain patients — is less certain. For example, 
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a study of chronic pain patients given a five-day anesthetic dose of ketamine did not 
discover any cognitive deficits six weeks later (Koffler et al., 2007). Longer follow-up 
periods in patients with depression or pain using repeated ketamine have not yet been 
used to examine the presence of persistent cognitive deficits (Short et al., 2018).  
 In the context of frequent recreational use of ketamine, reports of ketamine 
craving, compulsive behavior, and tolerance are commonly reported. Pigeons and 
monkeys self-administer rising doses of ketamine over time (Short et al., 2018). 
Recreational users of ketamine frequently also self-administer increasing doses over time. 
A ketamine withdrawal syndrome may exist, but such a syndrome has not been well-
studied or characterized (Morgan & Curran, 2012). Documented ketamine dependence 
has rarely been seen. In the past 20 years, fewer than 15 such cases have been reported 
(Short et al., 2018). However, no large studies have attempted to determine the incidence 
rate of ketamine dependency. In consequence, the risk of dependency remains difficult to 
quantify (Morgan & Curran, 2012). 
 
Other Routes of Administration 
 Patients receiving intranasal esketamine experienced a similar side effect profile 
to those receiving intravenous ketamine. Transient elevations in blood pressure, 
dissociative effects, and perceptual symptoms were common in patients, but resolved 
within two hours in most cases. Dissociative and perceptual symptoms tended to decrease 
with repeated dosing (Daly et al., 2018). Studies using oral, subcutaneous, or 
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intramuscular routes of administration tend to record fewer side effects than studies using 
intravenous routes (Short et al., 2018). 
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MECHANISM OF ACTION 
 
 Ketamine’s mechanism of action is likely to be complex. The drug has multiple 
effects on glutamatergic transmission. Ketamine inhibits GABAergic interneurons — 
increasing glutamate release — and activates AMPARs. Downstream effects on 
intracellular mammalian target of rapamycin (mTOR) and extracellular signal-regulated 
kinase (ERK) signaling may be critical to ketamine’s effects. Ketamine also inhibits 
glycogen synthase kinase 3 (GSK3) and blocks apoptotic extrasynaptic NMDARs. All 
these effects of ketamine are predicted to increase BDNF production, but tests of BNDF 
levels in ketamine treated patients display mixed findings.  
 Studies comparing ketamine to other NMDAR antagonists and enhancers indicate 
that ketamine’s antagonism of NMDARs alone might not account for its antidepressant 
effect. Instead, multiple actions by ketamine on the glutamate system converge to 
produce synaptogenesis, which might be the key mechanism in alleviating depression. 
 Researchers have also parsed the differential effects of ketamine’s two 
stereoisomers and delineated ketamine’s varied impact across a number of brain regions. 
The two stereoisomers of ketamine, (R)- and (S)-ketamine, seem to have differing 
mechanisms of action, efficacy, and side effect profiles. Researchers have used brain 
imaging to show how ketamine alters regional neural activity and connectivity. Ketamine 
increases activity and connectivity across some regions while decreasing them across 
others. 
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Inhibition of GABAergic Interneurons  
 Initially, ketamine’s mechanism of antidepressant action was thought to be 
inhibition of NMDARs. Ketamine binds multiple targets, but binds NMDARs with the 
highest affinity (Zarate et al., 2006). In particular, ketamine binds to a site within the 
NMDAR ion channel, acting as a non-competitive antagonist (Murrough et al., 2017). 
These receptors mediate ketamine’s anesthetic effects (Zanos et al., 2016).  
 The initial hypothesis of multiple research groups was that ketamine inhibited 
NMDARs on GABA-releasing interneurons (Figure 3). These interneurons synapse onto 
prefrontal pyramidal glutamatergic neurons. Inhibition of the GABA releasing 
interneurons by ketamine was thought to disinhibit downstream prefrontal pyramidal 
glutamatergic signaling. These disinhibited pyramidal neurons then released a surge of 
glutamate. The resultant increase in glutamatergic transmission in mood associated brain 
regions was thought to be responsible for ketamine’s antidepressant effect (Li et al., 
2010; Murrough et al., 2017; Zanos et al., 2016). 
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Figure 3: Ketamine Inhibiting NMDARs on GABAergic Neurons Causes a Burst of 
Glutamate Release. As shown on the leftmost neuron, ketamine binds pre-synaptic 
NMDARs, leading to decreased GABA release from these interneurons. With GABA 
release lowered, downstream glutamate exocytosis by prefrontal pyramidal neurons 
(middle neuron) is enhanced. This surge of glutamate activates AMPA receptors, as 
depicted in the rightmost neuron. Early research implicated this sequence of events as 
underlying ketamine’s antidepressant effect. AMPA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; GABA, γ–aminobutyric acid; GABAA, γ–aminobutyric acid A 
receptor; Gln, glutamine; GLS, glutaminase; Glu, glutamate; mGluR, metabotropic 
glutamate receptor; NMDAR, N-Methyl-D-aspartate receptor; VGLUT, vesicular 
glutamate transporter. Figure from (Kosten, Verhaeghe, wyffels, Stroobants, & Staelens, 
2018). 
 
Activation of Intrasynaptic AMPARs 
 Low dose ketamine also directly or indirectly activates intrasynapatic AMPARs. 
AMPAR activation is a prerequisite for intrasynpatic NMDAR activation. Ketamine may 
then indirectly enhance signaling at intrasynaptic NMDARs as a consequence of 
ketamine’s activation of AMPARs. This activation of AMPARs may be key to 
ketamine’s mechanism of action (Murrough et al., 2017). 
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 A research group also recently discovered a ketamine metabolite that activates 
AMPARs (Figure 4). The ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) was 
shown to induce antidepressant effects in animal models. Stopping metabolism of 
ketamine to HNK blocked ketamine’s antidepressant effects in these same animal 
models. In rats, HNK does not inhibit NMDARs of interneurons; instead, HNK increases 
the frequency and amplitude of AMPAR mediated excitatory post-synaptic potentials 
(Zanos et al., 2016). Blockade of AMPARs abolishes HNK’s antidepressant effect in 
mice. AMPAR blockade also reduces the antidepressant effect of other compounds, 
including the NMDAR partial antagonist GLYX-13; the mGluR2 and mGluR3 antagonist 
LY341495; and the muscarinic acetylcholine receptor antagonist scopolamine (Murrough 
et al., 2017).  
 The above research on ketamine’s activation of AMPARs indicates that blockade 
of interneuron NMDARs may not be necessary for ketamine’s antidepressant effect, as 
was originally believed (Zanos et al., 2016). In short, Zanos et al. (2016) argue that 
activation of AMPARs by HNK is necessary and sufficient for ketamine’s antidepressant 
effects in animal models. 
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Figure 4: Ketamine Metabolite HNK Activates AMPARs. Ketamine is metabolized 
into HNK, which is thought to directly activate intrasynaptic AMPARs. AMPAR 
activation then assists in the activation of intrasynaptic NMDARs. In animal models, 
halting metabolism of ketamine into HNK or blocking AMPARs eliminates ketamine’s 
antidepressant effect. AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor; HNK, (2R,6R)-hydroxynorketamine; NMDAR, N-Methyl-D-aspartate receptor. 
Figure from (Malinow, 2016). 
 
BDNF, ERK–Akt, and mTORC1 Signaling Enhance Synaptic Plasticity  
 Ketamine quickly alters intracellular signaling pathways of neurons in the PFCs 
of rats (Li et al., 2010). By activating AMPARs and intrasynaptic NMDARs, ketamine 
increases cytosolic Ca2+ concentration within neurons (Figure 5). The rise in Ca2+  
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Figure 5: Ketamine Increases BDNF, ERK-Akt, and mTOR Signaling While 
Inhibiting GSK3. Ketamine inhibits pre-synaptic NMDARs of GABAergic neurons. The 
decrease in GABA disinhibits glutamate release. Elevated glutamate activates AMPARs, 
which may also be directly activated by ketamine or its metabolite HNK. AMPAR 
activation triggers Ca2+ influx through other channels, followed by exocytosis of the 
neurotrophin BDNF. BDNF binds TRKB receptors, activating ERK, Akt, and mTOR 
signaling. Translation of synaptic proteins, as well as of BDNF itself (not shown), results 
because of the increase in mTOR activity. Increased amounts of these proteins enhance 
synapse formation and strength, causing antidepressant effects. Additionally, ketamine — 
like lithium — inhibits GSK3 (not shown). Inhibition of GSK3 also increases mTOR 
activity and eventually synaptogenesis. 4E-BP1, eukaryotic translation initiation factor 
4E-binding protein 1; Akt, Protein Kinase B; AMPAR, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor; Arc, activity-regulated cytoskeleton-associated protein; 
BDNF, brain-derived neurotrophic factor; eEF2, eukaryotic elongation factor 2; eEF2K, 
eukaryotic elongation factor 2 kinase; eIF4E, eukaryotic translation initiation factor 4E; 
ERK, extracellular signal-regulated kinase; GABA, γ–aminobutyric acid; GluR1, 
glutamate receptor 1 subunit; GSK3, glycogen synthase kinase 3; HNK, (2R,6R)-
hydroxynorketamine; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian 
target of rapamycin; NMDAR, N-Methyl-D-aspartate receptor; p70S6K, ribosomal protein 
S6 kinase beta-1; PI3K, phosphoinositide 3-kinase; PSD95, post-synaptic density protein 
95; TRKB, tropomyosin-related kinase B; VDCC, voltage-dependent calcium channels. 
Figure from (Scheuing, Chiu, Liao, & Chuang, 2015). 
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concentration triggers exocytosis of BDNF. BDNF binds tropomyosin-related kinase B 
(TRKB) receptors on neurons. TRKB receptor activation then enhances ERK–Akt and 
mammalian target of rapamycin complex 1 (mTORC1) signaling (Murrough et al., 2017). 
Activation of mTOR is dose dependent, occurring with the lower doses of ketamine used 
for depression. The higher ketamine doses used in anesthesia do not activate mTOR (Li 
et al., 2010). Increased signaling in ERK-Akt and mTORC1 pathways, in turn, enhances 
the translation of several proteins. These proteins include GluR1 (also called GluA1), 
post-synaptic density protein 95 (PSD95), and BDNF itself (Murrough et al., 2017). The 
induction of mTOR also increases the amount of the presynaptic protein synapsin I (Li et 
al., 2010). 
 By elevating the levels of these proteins, ketamine enhances synapse formation. 
GluR1, PSD95, and synapsin I are important for the formation, maturation, and 
maintenance of synapses and new synaptic spines (Li et al., 2010). Synapsin I, in 
particular, is critical for presynaptic plasticity enhancement and long-term potentiation 
(Kushner et al., 2005). Levels of GluR1, PSD95, and synapsin I remain higher for up to 
72 hours after ketamine administration (Li et al., 2010). Increased BDNF also enhances 
the formation and maturation of synapses (B. Hu, Nikolakopoulou, & Cohen-Cory, 
2005). The effects peak at two to six hours after ketamine infusion. Within two hours, 
mTOR phosphorylation — which indicates active mTOR signaling — returns to baseline 
(Li et al., 2010). In summary, ketamine infusion — operating through induction of 
BDNF, ERK-Akt, and mTORC1 pathways — results in the production of proteins that 
enhance synaptogenesis.  
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 Several lines of evidence support the link between ketamine, AMPAR activation, 
synaptogenesis, and antidepressant effects. Two-photon imaging and electrophysiological 
studies in rats have demonstrated ketamine’s ability to induce the formation of new 
synapses and strengthen existing synapses. Blockade of the mTOR pathway in rat PFCs 
abolished ketamine’s antidepressant action in animal models of depression. Additionally 
in rats, selective inhibition of AMPARs blocked phosphorylation-mediated activation of 
ERK, Akt, and mTOR and also abolished ketamine’s antidepressant effect (Li et al., 
2010).  
 Despite the research supporting this chain of events, not all efforts to replicate the 
links between ketamine administration, an increase in mTORC1 signaling, and synaptic 
plasticity have succeeded (Murrough et al., 2017). Rapamycin, as an inhibitor of the 
mTOR pathway, might be expected to block ketamine’s antidepressant effects. However, 
Autry et al. (2011) found that rapamycin did not, in fact, block ketamine’s antidepressant 
effects in mice models. Additionally, rapamycin alone has antidepressant effects in mice 
when give daily for four days, but not when given after a single injection (Cleary et al., 
2008). As such, the role of mTOR signaling in ketamine’s antidepressant effect still 
remains unclear at present (Chun Yang et al., 2018). 
 
Inhibition of Glycogen Synthase Kinase 3 Enhances Synaptic Plasticity 
 Ketamine is also thought to enhance synaptic plasticity through its effect on 
GSK3. Ketamine — like lithium — inhibits GSK3. Activation of GSK3 downregulates 
synaptic plasticity pathways (Figure 5). In consequence, ketamine and lithium disinhibit 
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pro-plasticity pathways. In hippocampal neurons, ketamine’s inhibition of GSK3 causes 
an increase in GluR1 trafficking to the cell membrane. The increase in membranal GluR1 
enhances AMPAR signaling and long-term potentiation (Murrough et al., 2017). 
 
Ketamine Inhibits Extrasynaptic NMDARs  
 Ketamine is believed to block extrasynaptic NMDARs and, in doing so, provide a 
neuroprotective effect that inhibits apoptosis. Activation of extrasynaptic NMDARs 
inhibits protein translational machinery, including mTORC1 and eukaryotic elongation 
factor 2 (eEF2). Ketamine’s blockade of extrasynaptic NMDARs causes eEF2 to be 
disinhibited (Figure 6). For this reason, the inhibition of extrasynaptic NMDARs by 
ketamine upregulates translation. Enhanced translation of BNDF and synaptic proteins 
increases synapse formation as well as synaptic strength, spine diameter, and density 
(Murrough et al., 2017). 
 Chronic stress has been shown to decrease intrasynaptic glutamatergic signaling 
and increase extrasynaptic glutamatergic signaling within hippocampal and cortical 
glutamatergic synapses. These brain regions have then shown reduced BDNF signaling. 
Ketamine rapidly reverses the effects of chronic stress on BDNF levels in the 
hippocampus (Murrough et al., 2017). 
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Figure 6: Activation of Intrasynaptic Versus Extrasynaptic NMDARs. When 
glutamate — shown as green dots — binds NMDARs within synapses, mTOR signaling 
is activated and synaptogenesis results. In contrast, the binding of glutamate to 
extrasynaptic NMDARs decreases synaptogenesis. Glutamate binding to extrasynaptic 
NMDARs causes a local influx of Ca2+. The increased Ca2+ at this location activates eEF2 
kinase, possibly through Ca2+ induced phosphorylation of eEF2 kinase at particular 
residues. Activation of eEF2 kinase causes phosphorylation of eEF2, inactivating eEF2 
(not shown). Inactive eEF2 diminishes BDNF translation and synaptogenesis. However, 
ketamine — shown here as purple diamonds — blocks glutamate from binding to 
extrasynaptic NMDARs, preventing activation of eEF2 kinase and reversing this chain of 
events. In this fashion, ketamine allows eEF2 to remain active and enhances translation 
of synaptic proteins. BDNF, brain-derived neurotrophic factor; eEF2, eukaryotic 
elongation factor 2; mTOR, mammalian target of rapamycin; NMDAR, N-Methyl-D-
aspartate receptor. Information on extrasynaptic NMDAR mediated activation of eEF2 
kinase from (Autry et al., 2011). The effect of rising cytosolic Ca2+ on the 
phosphorylation and the activity of eEF2 kinase and eEF2 is from (Heise et al., 2014). A 
description of how Ca2+ influx at extrasynaptic versus synaptic locations can cause 
differences in cell activity can be found in (Hardingham & Bading, 2010). Figure adapted 
from (Chan, Matthews, & Burnet, 2017). 
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Predicted Increase in BDNF 
 Based on the downstream effects of ketamine’s activation of AMPARs and 
blockade of extrasynaptic NMDARs (as outlined above), an increase in BDNF within the 
brain would be expected following ketamine administration. Studies evaluating this 
outcome are limited in that they have only been able to sample circulating levels of 
BDNF rather than BDNF in the central nervous system. Results have been mixed. One 
study showed an increase in circulating BDNF in those patients with treatment resistant 
depression who responded to ketamine (Murrough et al., 2017). In contrast, an earlier  
study in depressed patients demonstrated no increase in circulating BDNF following 
ketamine administration despite improvements in mood (Machado-Vieira et al., 2009). 
 
Contrast Between Ketamine and Other NMDAR Agents 
 A number of other NMDAR modulating agents have been tested for 
antidepressant effects. Memantine is an NMDAR antagonist, but does not increase 
hippocampal BDNF translation and has no antidepressant effects. As such, NMDAR 
antagonism may not be sufficient for an antidepressant effect.  
 Though ketamine is an NMDAR antagonist, NMDAR enhancers have also been 
show to display anti-depressant effects. The NMDAR enhancers D-cycloserine, GLYX-
13, NRX-1074, and sarcosine all show antidepressant effects in initial studies. These 
agents are believed to activate AMPARs and intrasynaptic NMDARs, leading to 
downstream increases in BDNF and synapotogenesis. That these contrasting agents also 
initiate an antidepressant effect suggests that a complex mechanism of action may 
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underlie ketamine’s antidepressant capacity. Multiple modifications of glutamate 
signaling may be responsible for ketamine’s antidepressant effect (Murrough et al., 
2017).  
 
Differential Effects of (R)- Versus (S)-Ketamine 
 Recent research has uncovered different efficacy and side effect profiles for 
ketamine’s two stereoisomers. In animal models of depression, both (R)- and (S)-
ketamine have antidepressant effects. However, (R)-ketamine’s effects are stronger and 
last longer. Additionally, (R)-ketamine does not produce psychotomimetic side effects 
and appears to be less addictive than (S)-ketamine (Chun Yang et al., 2018).   
 (R)- and (S)-ketamine may operate through different intracellular pathways. In a 
study using the chronic social defeat model (Chun Yang et al., 2018), mice were exposed 
to an aggressor mouse for 10 minutes daily for 10 days. These stressed mice then 
received either (R)- or (S)-ketamine. Both enantiomers had antidepressant effects. 
Rapamycin and AZD8055 — both mTOR inhibitors — blocked the antidepressant effect 
only of (S)-ketamine. The ERK inhibitor SL327 blocked the antidepressant effect only of 
(R)-ketamine.  
 A discrepancy does exist regarding these results. Ketamine is normally 
administered as a racemic mixture. As a consequence, one might expect rapamycin to 
diminish ketamine’s antidepressant effect only partially (Chun Yang et al., 2018). 
However, a previous study has found that rapamycin abolishes ketamine’s antidepressant 
effect completely (Li et al., 2010). In contrast, another study found rapamycin to have no 
		
44 
effect on ketamine’s antidepressant capacity (Autry et al., 2011). The reason for this 
discrepancy is unknown at this time (Chun Yang et al., 2018).  
 (R)-ketamine has fewer dissociative side effects than (S)-ketamine. (S)-ketamine has 
a 3 to 4 times higher affinity for NMDARs than (R)-ketamine. For that reason, (S)-
ketamine is the more potent anesthetic and produces more psychotomimetic side effects 
(Chun Yang et al., 2018).  
 (R)-ketamine does not affect mTOR signaling, which may mean that (R)-ketamine 
is less likely to be addictive than racemic ketamine or (S)-ketamine. When habit-forming 
drugs are used, activation of mTOR signaling in the brain is associated with reward and 
excess drug seeking (Chun Yang et al., 2018). Results from mice studies using the 
conditioned place preference paradigm show behavioral differences in the effects of (R)-
ketamine and (S)-ketamine, as described below (C. Yang et al., 2015).  
 Conditioned place preference occurs when animals prefer to spend time in a 
location because that place has been associated with rewarding events. The paradigm is 
used to measure the rewarding effects of addictive drugs (Huston, Silva, Topic, & Müller, 
2013). (S)-ketamine increases the time mice spent in areas where they received the (S)-
ketamine, whereas (R)-ketamine does not. These results indicate that (R)-ketamine may 
have fewer or none of the addictive properties associated with (S)-ketamine and racemic 
ketamine (C. Yang et al., 2015).  
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Regional Changes in Brain Activity and Connectivity 
 When examined with brain imaging, depressed patients show a number of 
abnormalities in regional brain activity and connectivity. Administration of ketamine 
results in changes in activity in some of these brain regions and in the links between 
regions. This section will assess changes in the lateral habenula (LHb), PFC, anterior 
cingulate cortex (ACC), and amygdala. Changes specific to bipolar depression will also 
be examined. 
 The LHb inhibits the reward centers of the brain, namely, the dopaminergic 
ventral tegmental area and the serotonergic dorsal raphe nuclei. The LHb primarily 
contains glutamatergic neurons. A number of studies show that hyperactivity of the LHb 
is associated with depression (Y. Yang et al., 2018).  
 Animal studies show that ketamine’s antidepressant effect may occur in part 
through the LHb. In rats bred for congenital learned helplessness, local infusion of 
ketamine into the LHb produced rapid antidepressant effects. These antidepressant effects 
were demonstrated in both the forced swim test and the sucrose preference test (Y. Yang 
et al., 2018).  
 Burst firing of neurons in the LHb enhances network synchronization with other 
parts of the brain and may have a stronger inhibitory effect on downstream reward 
centers. The congenital learned helplessness rats showed increased burst firing in their 
LHbs in comparison to control rats. Optogenetic techniques demonstrated that increasing 
LHb burst firing in mice using photostimulation could drive depression-like phenotypes 
in the real-time place aversion assay and forced swim test (Y. Yang et al., 2018).  
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 Ketamine was found to reduce burst firing — but not tonic firing — in the LHbs 
of mice. The drug is thought to reduce burst firing by blocking NMDARs. Other agents 
that block NMDARs also reduced burst firing, but agents that blocked AMPARs only 
reduced burst firing slightly. These results might in part explain how ketamine is able to 
produce an antidepressant effect within hours, but do not account for ketamine’s longer 
acting antidepressant effects. As discussed above, increased BDNF and synaptogenesis 
might instead account for ketamine’s longer acting antidepressant effects (Y. Yang et al., 
2018).  
 The PFC is involved in working memory, self-regulation, and executive function 
(Akil et al., 2018). In patients with MDD, ketamine increases pooled 1H-MRS measures 
of glutamate, glutamine, and GABA in the PFC within one hour of administration. The 
transient elevation of glutamate caused by ketamine administration is thought to enhance 
synaptic plasticity. Transient activation of synapses can upscale activity in a brain region 
and enhance synaptic strength in that area by increasing AMPAR insertion and synaptic 
density. These elevated glutamate levels are tied to ketamine’s dissociative effects and a 
correlation has been found between the degree of dissociative effects and the strength of 
ketamine’s antidepressant effect. This possibility seems to indicate that it may be difficult 
to separate ketamine’s antidepressant effect from unwanted dissociative effects 
(Murrough et al., 2017). 
 In resting-state functional connectivity magnetic resonance imaging, global brain 
connectivity is a measure of the degree of correlation between the activity in any 
particular brain voxel and all the other voxels of the brain. Patients with depression have 
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reduced global brain connectivity between the PFC and the rest of the brain. They also 
have increased connectivity of the posterior cingulate, precuneus, lingual gyrus, and 
cerebellum with the rest of the brain. By 24 hours following ketamine administration, 
depressed patients showed an increase in PFC connectivity and a decrease in cerebellum 
connectivity. In effect, ketamine administration reverses the major global brain 
connectivity abnormalities seen in depressed patients (Abdallah et al., 2017). 
 Inducing sadness in healthy controls has been shown to increase activity in the 
subgenual ACC. Counter intuitively however, depressed patients show resting state 
hypometabolism in this brain area (Phan, Wager, Taylor, & Liberzon, 2002). In normal 
controls examined by functional magnetic resonance imaging, ketamine decreases the 
blood oxygen level-dependent (BOLD) signal in the subgenual ACC. In patients with 
MDD by contrast, ketamine increases the BOLD signal in the ACC. This increase was 
correlated with some measures of ketamine’s antidepressant effect (Murrough et al., 
2017). 
 The amygdala coordinates brain responses to affective stimuli. Depressed patients 
show higher activity in the amygdala when exposed to negative emotional stimuli. In 
normal controls, ketamine decreases the amygdala’s response to negative affective 
stimuli, but not positive stimuli (Scheidegger et al., 2016). In MDD patients following 
ketamine administration, increased activation of the amygdala in response to happy faces 
and decreased activation in response to angry faces correlated with the degree to which 
the depression scores of these patients declined (Reed et al., 2018).  
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 A positron emission tomography study of patients with bipolar depression 
(Nugent et al., 2014) examined changes occurring in response to ketamine. Decreases in 
depression were correlated with increases in the metabolism of the right ventral striatum, 
the subgenual ACC, and the dorsal cingulate cortex.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Based on the available evidence, ketamine appears to be an effective, rapidly 
acting antidepressant treatment. A single administration remains effective for about a 
week. Ketamine treats both major depression and bipolar depression, though initial 
results show the drug is relatively more effective in major depression. Notably, ketamine 
shows efficacy in treatment resistant populations that have failed other antidepressant 
therapies. Future studies might further test ketamine’s relative efficacy in bipolar 
depression and in other subtypes of depression, like post-partum depression or depression 
with anxious distress. 
 The conclusion that ketamine is effective for depression is weakened by the 
inadequacy of blinding procedures in the existing RCTs. Trials that have used midalozam 
as a control show a smaller antidepressant effect for ketamine compared to trials that used 
saline as a control. Even in trials that used midalozam as a control, subjects could 
correctly identify whether they received ketamine or not. The evidence in favor of 
ketamine’s efficacy would be strengthened going forward by finding an active placebo 
control that kept patients and treatment providers blind to the treatment administered. 
 Following the initial work establishing ketamine’s effectiveness, further research 
has tried to refine treatment protocols and enhance ketamine’s effects. At this time, a 
dose of 0.5 mg/kg appears to be optimal. If non-intravenous routes of ketamine 
administration demonstrate efficacy and safety, ketamine could potentially be used as a 
more routine clinical agent. In this regard, the development of intranasal ketamine 
administration is a beneficial step forward. Prolonged ketamine infusions do not seem to 
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prolong the antidepressant effect. Repeated ketamine infusions or combination therapy 
with CBT may sustain ketamine’s effect, but work in this area is still preliminary. If 
repeated ketamine infusions or combination treatments are found to create long lasting 
antidepressant effects, ketamine’s clinical utility would increase considerably.  
 At present, ketamine is particularly promising in scenarios where rapidity of 
action is needed. These situations include adding ketamine to escitalopram treatment to 
accelerate the achievement of response and remission and also administering ketamine as 
an acute treatment for patients at risk of suicide. In treating suicidal ideation acutely, 
ketamine may possess a more favorable side effect profile and the potential for longer 
lasting beneficial effects with repeat infusions or combination treatments in comparison 
to the current standard of care, ECT. Further research establishing ketamine’s utility as an 
add-on to conventional antidepressants and as an acute anti-suicide agent may be fruitful. 
At this time, significant unknowns remain, however, in whether ketamine’s anti-suicide 
therapeutic effects can be prolonged.   
 Ketamine is largely safe when single doses are used under clinical supervision. 
Acute side effects — e.g., dissociation, elevation of blood pressure, and confusion — are 
common, but subside within a few hours of administration. Insufficient data exists to 
make conclusions about ketamine’s long-term risk, particularly with repeated doses. 
Potential long-term risks include genitourinary damage, hepatotoxicity, cognitive deficits, 
and dependence. Most studies only monitored side effects in a passive fashion and only 
monitored side effects during the acute treatment period (Short et al., 2018). Uncertainty 
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about long-term side effects leaves the clinical utility of repeated ketamine doses in doubt 
at the present time. 
 In the future, studies would benefit from long-term monitoring for side effects and 
active, structured inquiry in regards to known or potential side effects (Short et al., 2018). 
In general, structured questioning increases the frequency of recorded drug side effects 
compared to unstructured interviewing (Naranjo, Busto, & Sellers, 1982). Collecting 
information on comorbidities, concomitant medications, and safety would also be useful 
in future studies. The differential side effect profile of ketamine enantiomers and 
metabolites is another area to be investigated in the future (Short et al., 2018).  
 Ketamine’s mechanism of action is likely to be multi-pronged. On the molecular 
level, inhibition of GABAergic interneurons, enhanced AMPAR activation, increased 
mTOR and ERK-Akt signaling, blockade of extrasynaptic NMDARs, inhibition of 
GSK3, and increased BNDF production may all be involved and potentially interlinked. 
In the future, studies of compounds that manipulate particular aspects of this system — 
like inhibition of mTOR by rapamycin or enhancement of NMDAR signaling by 
sarcosine — may continue to help isolate the contribution or non-contribution of these 
mechanisms to ketamine’s antidepressant effect.  
 Brain imaging shows changed activity and connectivity across particular brain 
regions following ketamine administration. Decreased burst firing in the LHb, increased 
activity in the PFC and subgenual ACC, and altered response in the amygdala to 
emotionally salient stimuli may be integral to ketamine’s mechanism of action.  
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 There may be an underlying difference in the mechanisms that constitute 
ketamine’s antidepressant effect within the first hours of administration and those that 
sustain the effect over the following days. For example, direct infusion of ketamine into 
the LHb produces an antidepressant effect in mice within an hour of infusion, but it 
remains unclear if decreased burst firing in the LHb has a role in ketamine’s 
antidepressant effect over the following days (Y. Yang et al., 2018). Future research may 
refine understanding of potential mechanisms of action by distinguishing between those 
that operate within hours of ketamine administration and those that occur subsequently. 
Future research could also focus on isolating the actions of (R)- and (S)-ketamine, as well 
as the actions of individual ketamine metabolites. The potentially differing mechanisms 
of these molecules may cause differences in antidepressant efficacy and side effects. 
 Though this thesis has focused on the glutamate system in attempting to 
understand ketamine’s mechanism of action, other systems may be involved. Research is 
being conducted on the dopamine, opioid, and immune systems as mediators of 
ketamine’s antidepressant effect. For example, ketamine may work in part by decreasing 
the pro-inflammatory cytokines interleukin-1β, interleukin-6, and tumor necrosis factor. 
Decreased levels of these cytokines would, in turn, disinhibit pro-plasticity pathways. 
However, the extant research on ketamine and cytokines remains in early stages and 
findings contradict one another. Ketamine may also induce epigenetic changes that may 
be integral to its antidepressant effect (Murrough et al., 2017).  
 To develop a more complete portrait of the neurobiology of depression and its 
potential treatments, researchers will seek to integrate findings about the glutamate, 
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monoamine, opioid, and immune systems with those on regional alterations in brain 
activity. At this stage, it remains unknown if depression will be found to have a single 
final common pathway of origin. Instead, depression may in fact represent multiple 
diseases, with distinct phenotypes that require different treatments. Research on ketamine 
represents an important tool in tackling these questions. In the meantime, ketamine itself 
has the potential to be developed into a promising new treatment for depressed patients.  
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